These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11563054)

  • 1. The role of antisense oligonucleotides in the wave of genomic information.
    Baker BF
    Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):397-9. PubMed ID: 11563054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides as therapeutics for malignant diseases.
    Ho PT; Parkinson DR
    Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of antisense oligonucleotides for gene functionalization and target validation.
    Bennett CF; Cowsert LM
    Curr Opin Mol Ther; 1999 Jun; 1(3):359-71. PubMed ID: 11713801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
    Henry SP; Marcusson EG; Vincent TM; Dean NM
    Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico determination of potential antisense targets for human beta-globin variants.
    Arrigo P; Ivaldi G; Cardo PP
    In Silico Biol; 2002; 2(2):143-50. PubMed ID: 12066838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense and RNAi: powerful tools in drug target discovery and validation.
    Lavery KS; King TH
    Curr Opin Drug Discov Devel; 2003 Jul; 6(4):561-9. PubMed ID: 12951819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overview of target validation and the impact of oligonucleotides.
    Jones SW; Lindsay MA
    Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antisense oligonucleotides for target validation and gene function determination.
    Taylor MF
    IDrugs; 1999 Aug; 2(8):777-81. PubMed ID: 16127653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oligonucleotide-based knockdown technologies: antisense versus RNA interference.
    Achenbach TV; Brunner B; Heermeier K
    Chembiochem; 2003 Oct; 4(10):928-35. PubMed ID: 14523910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and analysis of antisense oligonucleotide activity in cell culture.
    Baker BF; Condon TP; Koller E; McKay RA; Siwkowski AM; Vickers TA; Monia BP
    Methods; 2001 Feb; 23(2):191-8. PubMed ID: 11181038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo.
    Simons M; Edelman ER; DeKeyser JL; Langer R; Rosenberg RD
    Nature; 1992 Sep; 359(6390):67-70. PubMed ID: 1522889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi: a novel antisense technology and its therapeutic potential.
    Dallas A; Vlassov AV
    Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons.
    Yu C; Brussaard AB; Yang X; Listerud M; Role LW
    Dev Genet; 1993; 14(4):296-304. PubMed ID: 7693387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
    Oberbauer R
    Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
    Kausch I; Böhle A
    Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topical and transdermal delivery of antisense oligonucleotides.
    Brand RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):244-8. PubMed ID: 11497348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
    Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
    Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards high-throughput functional target discovery in angiogenesis research.
    van Beijnum JR; Eijgelaar WJ; Griffioen AW
    Trends Mol Med; 2006 Jan; 12(1):44-52. PubMed ID: 16325471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Control of gene expression by antisense nucleic acids].
    Lebleu B; Clarenc JP; Degols G; Leonetti JP; Milhaud P
    C R Seances Soc Biol Fil; 1992; 186(5):560-6. PubMed ID: 1305901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro and in vivo pharmacologic activities of antisense oligonucleotides.
    Mirabelli CK; Bennett CF; Anderson K; Crooke ST
    Anticancer Drug Des; 1991 Dec; 6(6):647-61. PubMed ID: 1663361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.